Inclusion Criteria:

- Histologically confirmed endometrial cancer

- Advanced or recurrent disease

- Stage IIIB or IIIC disease

- Stage IIIA disease allowed provided there is serosal involvement or direct
extension or metastasis to the adnexa

- No stage IIIA confirmed by only positive peritoneal washings

- Stage IVA or IVB disease

- Failed local therapy or considered incurable with local therapy

- Measurable or evaluable disease

- Not required for newly diagnosed stage III or IV disease with no remaining
disease after surgery

- Performance status Gynecology Oncology Group (GOG) 0-1

- Life expectancy at least 12 weeks

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 10 g/dL

- Meets 1 of the following criteria:

- Alkaline phosphatase (AP) normal AND aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN)

- AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN

- AP ≤ 5 times ULN AND AST or ALT normal

- Bilirubin normal

- No acute hepatitis

- Creatinine ≤ 1.5 mg/dL

Exclusion Criteria:

- Known hypersensitivity to docetaxel or polysorbate 80

- Severe infection

- Septicemia

- Pregnant or nursing

- Positive pregnancy test

- Fertile patients must use effective nonhormonal contraception during and for at least
3 months after study treatment

- Peripheral neuropathy ≥ grade 2

- Severe gastrointestinal bleeding requiring a blood transfusion or hospitalization

- Other malignancy within the past 5 years except nonmetastatic, nonmelanoma skin
cancer or carcinoma in situ of the cervix

- Prior chemotherapy

- Prior radiotherapy